Nature Reviews Drug Discovery contents October 2014 Volume 13 Number 10 pp 709-780

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
October 2014 Volume 13 Number 10		Advertisement
Impact Factor 37.231 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Strategies to improve drug development for sepsis Mitchell P. Fink & H. Shaw Warren	PD-L1 E1L3N™ XP® Rabbit mAb #13684 Highly specific for PD-L1 (no cross-reactivity with other B7 family proteins) Detects endogenous levels of PD-L1 expression Validated for IHC, flow cytometry and other research applications Expert Technical Support   For Research Use Only. Not For Use In Diagnostic Procedures.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Powerful reasons to choose Reichert Surface Plasmon Resonance (SPR) systems for your lab  Reichert SPR systems beat the competition! Unparalleled performance. Unmatched sensitivity. Robust off-the-shelf fluidics. Low operating costs. Outstanding support for your applications from expert scientists. No better value. Compare for yourself.  ReichertSPR.com/advantage
Comment: Antimicrobial innovation: combining commitment, creativity and coherence Jos W. M. van der Meer, Robin Fears, Dame Sally C. Davies & Volker ter Meulen p709 | doi:10.1038/nrd4448 Urgent action to tackle antimicrobial resistance must take account of all the scientific opportunities available, find new resources to support academia and emphasize the importance of innovation to policy-makers and to the general public.Full Text | PDF
NEWS AND ANALYSIS		Top
Momentum builds around new antibiotic business models Asher Mullard p711 | doi:10.1038/nrd4455 The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume. PDF
False dawn for cystic fibrosis disease modifiers? David Holmes p713 | doi:10.1038/nrd4456 Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most common form of the disease. PDF
NEWS IN BRIEF Merck wins first PD1 sprint in US p715 | doi:10.1038/nrd4458 PDF
Illuminating interleukin-5 data p715 | doi:10.1038/nrd4459 PDF
Reanalyse this p715 | doi:10.1038/nrd4460 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming catalysts in Q4 2014 Andrew Ang p716 | doi:10.1038/nrd4449 PDF
Trial watch: Next-generation antimalarial from phenotypic screen shows clinical promise Megan Cully p717 | doi:10.1038/nrd4457 PDF
AN AUDIENCE WITH Story Landis p718 | doi:10.1038/nrd4454 Story Landis, ex-Director of the US National Institute of Neurological Disorders and Stroke, discusses how she has worked to address a crisis of basic research funding at the Institute. PDF
FROM THE ANALYST'S COUCH The cystic fibrosis drug market Basharut A. Syed & Bashar Hamad p721 | doi:10.1038/nrd4434 Current treatments for cystic fibrosis are largely symptomatic, but the first disease-modifying drug has recently been approved and others are progressing. This article examines the multitude of agents in the clinical pipeline and their potential market impact in the next 5 years. PDF
RESEARCH HIGHLIGHTS Top Cancer: Lipid kinase PIP5K1α as a new target in prostate cancer p723 | doi:10.1038/nrd4446 PDF Autoimmune disease: Getting to the root of hair loss in alopecia p724 | doi:10.1038/nrd4443 PDF Cardiovascular drugs: Engineered apyrase averts clot formation p724 | doi:10.1038/nrd4444 PDF Neuromuscular disorders: Beefing up the right splice variant to treat spinal muscular atrophy p725 | doi:10.1038/nrd4445 PDF Anticancer therapy: Bacterial treatment for cancer p726 | doi:10.1038/nrd4447 PDF IN BRIEF Cancer: Understanding resistance to antiangiogenic agents | Transplantation: Hydrogel safely delivers immunosuppressant | Psychiatric disorders: Enzyme inhibitor improves cognitive function | Drug design: Guidelines for macrocycle drug design PDF Drug Discovery JOBS of the week Faculty Position in Medicinal Chemistry for Cancer Drug Discovery St. Jude Children's Research Hospital (SJCRH) Non-invasive diagnosis and drug screening in neurological infections KU Leuven Head of Drug and RNAi Screening Platform UCLA PhD position The University of Hong Kong Tenure Track Position- Principal Investigator National Cancer Institute (NCI) More Science jobs from Drug Discovery EVENT 6th Annual Global Drug Delivery & Formulation Summit 09.02.15 Dusseldorf, Germany More science events from
PERSPECTIVES		Top
OPINION Caloric restriction mimetics: towards a molecular definition Frank Madeo, Federico Pietrocola, Tobias Eisenberg & Guido Kroemer p727 | doi:10.1038/nrd4391 Caloric restriction can promote health and extend the lifespan of model organisms, and diverse classes of compounds that mimic the biochemical and functional effects of caloric restriction have attracted considerable interest as potential pharmacotherapies for diseases such as diabetes and obesity. Kroemer, Madeo and colleagues propose a unifying definition of caloric restriction mimetics as agents that induce autophagy by promoting protein deacetylation, which could have implications for their development as drugs. Abstract | Full Text | PDF
REVIEWS		Top
Strategies to improve drug development for sepsis Mitchell P. Fink & H. Shaw Warren p741 | doi:10.1038/nrd4368 Sepsis is a potentially fatal systemic disease that is caused by microbial infection. Despite numerous clinical trials, no specific therapeutic agent has yet been approved for this indication. Here, Fink and Warren consider potential reasons for such failures and suggest possible strategies to overcome ongoing challenges, such as improving clinical trial design. Abstract | Full Text | PDF | Supplementary information
mRNA-based therapeutics — developing a new class of drugs Ugur Sahin, Katalin Karikó & Özlem Türeci p759 | doi:10.1038/nrd4278 The therapeutic potential of in vitro-transcribed mRNA (IVT mRNA) extends from prophylactic and therapeutic vaccines to applications such as protein replacement and genome engineering. In this Review, the authors describe the recent developments in the IVT mRNA field, discuss the class-specific challenges with regards to translating IVT mRNA into a biopharmaceutical, and provide an overview of IVT mRNA drugs in development for different indications. Abstract | Full Text | PDF
Advertisement
Nature Communications soon to be fully open access   From 20th October Nature Communications, will become fully open access for all new submissions. If an author has a manuscript they wish to submit to the journal via the subscription route, they must submit before 20th October. After this date all new submissions, if accepted, will be published open access and an article processing charge (APC) will apply. For any questions on the switch, open access or advice on policies and funding, visit our website, read the press release or contact our dedicated support team at openaccess@nature.com.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.